Lecture 11: Anti-inflammatory drugs NSAIDs Flashcards
Main groups of anti-inflammatory drugs
-Drugs that inhibit COX
–> non steroidal anti-inflammatory drugs (NSAIDs) => includes coxibs
- Antirheumatoid drugs (disease-modifying antirheumatic drigs (DMARDs) => together w/ immunosuppressants
- The glucocorticoids
- Anti-cytokines and other biopharmaceutical agents
- Antihistamines
-Drugs that control gout
Pharmacological actions of NSAIDs
- anti-inflammatory effect: modification of the inflammatory reaction.
- analgesic effect: reduction of certain types of pain.
- Antipyretic effect: lowering of body temp
the drugs do not induce hypothermia
Mehanism-based effects
- gastric irritation
-renal blood flow - inhibition of platelet function
- may increase the likelihood of thrombotic events (myocardial infarction & stroke
Compare the main types of COX enzymes and drugs that exhibit preferential action towards the different COX isoforms.
COX 1: constitutively expressed; in tissue; homeostasis; produce prostaglandins; knockout = healthy
COX 2: inducible form; in inflammatory cells; produces mediators; knockout = problems
selectivity: non selective to weakly selective to highly COX 1 or 2 selective
ex. aspirin weakly COX selective.
Chemical structures and the main pharmacological actions of NSAIDs
-Antipyretic effects
-Analgesic effects
-Anti-inflammatory effects
-Antipyretic effects: NSAIDs affect prostaglandin in hypothalamus = thermostat
–> prostaglandus synth induced by pyrogens = from fever
- Analgesic effects: lower PG that sensitive receptors to infl. mediators
–> inh. PG = relieve headache: vasodilator effect
-Anti-inflammatory effects: Suppress pain, swelling, ^ blood flow.
-> vasodilation
-> ederna reduced
-> pain reduced
Structures: classic NSAID = carboxylic acids ‘coxibs’ = have bulky group
Molecular pharmacology of NSAIDs
- COX-1 & 2 are honodiners in intracellular membranes
-> dioxygenase step (NSAIDs typically inhibit)
-> peroxidase step - NSAID comp. reversible
-enter hydrophobic channel - COX-2 is bulky side pocket so some drugs selective for COX-2 if they also bulky
- COX 1 selective, irreversible = aspirin
The main side effects of NSAIDs
GI side effects: from inhibit of gastric COX-1; local damage to mucosa symptomatic or asymptomatic
-> gastric discomfort, dyspesia, diarrhea, nausea vomiting, ulceration
Renal side effects: through inhibitions of prostanoids synth: maintain renal flow.
–> abuse = analgesic nephopethy
other: skin rxns, platelet aggregation, CNS, liver disorders, Reye’s syndrome
Study of aspirin
- earliest drugs synthesized
- most commonly consumed drugs
- it is approaching the status of a wonder drug that is of benefit not only inflammation, but in other conditions:
- cardiovascular disorders
- colonic, rectal and prostate cancer
- alzheimer’s disease
- Alters balance between TXA2 (promotes aggregation/ synthesis in platelets) and PGI2 (inhibits/ synthesis in endothelium)
- irreversibly inactivates COX-1
- oral administration selective for platelets.
-low doses of aspirin - once every 24-48h
- addictive
pharmacokinetics ——————
- weak acid (not ionized)
- absorption occurs in the iluem
- hydrolised by esterases in plasma/tissues/liver
- excretion higher in alkaline urine
- half-life of aspirin will depend on the doses
Side effects
- general NSAIDs unwated effects
- salicylism
–> ringing in ears
–> vertigo
–> decreased hearing
–> nausea and vomiting
- In CNS coma and respiratory depresssion
Study of acetaminophen
- paracetamol
- potent analgesic and antipyretic actions
- weaker anti-inflammatory effects
- not considered as NSAIDs
-given orally + well absorbed
- half-life 3-4h
-toxic doses 4-8h
-Inactivated in the liver (CYP enzymes)
Side effects
@ THERAPEUTIC DOSES
- allergic skin reactions
- kidney damage
- Acetaminophen overdose
TOXIC DOSES
- fatal hepatotoxicity
- liver enzymes catalysing the normal conjugation reactions are saturated.
- nausea and vomiting
Current status with coxibs
Vioxx -> causes serious risk of heart attacks so has been pulled out of market.
Diclofenac -> has similar risks of causing heart attacks but hasn’t been pulled from market.